Recently. a family of genes whose encoded proteins share amino acid sequence homology with Bcl-2 have been identified. This family of proteins include Bcl-2. Bcl-x and Mcl-l. which act as blockers of apoptosis. whereas others such as Bax and Bak appear to promote apoptosis (Oltvai. 1993 : Boise et al. 1995 . The biological mechanisms by which the Bcl-2 gene family regulate apoptosis remain uncertain. The Bax protein seems. however. to act as a central regulator within this multigene family. Several studies have demonstrated that increased Bax expression is associated with increased radio-and chemosensitivity to induction of apoptosis (Bargou et al. 1996 : Chresta et al. 1996 : Kitada et al. 1996 : Sakakura et al. 1996 : Stoetzer et al. 1996 : Thomas et al. 1996 : Wagener et al. 1996 . Information regarding the prognostic significance of Bax in human tumours is scarce. It has, however, been shown that reduced Bax expression correlates with tumour progression and shortened sunrival in breast adenocarcinomas (Krajewski et al. 1995).
The growth rate of a tumour depends on both the proliferation and loss of tumour cells (Reed. 1994) . Loss of cells can occur by necrosis or apoptosis. Necrosis is a result of environmental factors. such as loss of blood supply. whereas apoptosis represents programmed cell death triggered by intrinsic cellular mechanisms. Apoptosis occurs in virtually all tissues that have the capacity for self-renewal. including malignant tumours (Searle et al. 1973 : Wyllie. 1985 .
Recently. a family of genes whose encoded proteins share amino acid sequence homology with Bcl-2 have been identified. This family of proteins include Bcl-2. Bcl-x and Mcl-l. which act as blockers of apoptosis. whereas others such as Bax and Bak appear to promote apoptosis (Oltvai. 1993 : Boise et al. 1995 . The biological mechanisms by which the Bcl-2 gene family regulate apoptosis remain uncertain. The Bax protein seems. however. to act as a central regulator within this multigene family. Several studies have demonstrated that increased Bax expression is associated with increased radio-and chemosensitivity to induction of apoptosis (Bargou et al. 1996 : Chresta et al. 1996 : Kitada et al. 1996 : Sakakura et al. 1996 : Stoetzer et al. 1996 : Thomas et al. 1996 : Wagener et al. 1996 . Information regarding the prognostic significance of Bax in human tumours is scarce. It has, however, been shown that reduced Bax expression correlates with tumour progression and shortened sunrival in breast adenocarcinomas (Krajewski et al. 1995) .
Moreover. it has been demonstrated that the bcl-2/bax mRNA expression ratio represents a prognostic marker in low-grade urinary (Ploton et al. 1986 ). AgNOR staining. which is one of several biological proliferative markers currently used, is as a rule expressed as mean counts (mAgNOR). Several studies on malignant tumours. including head and neck squamous cell carcinomas. have shown that the mAgNOR counts were higher in tumours with poor prognosis than in those with good prognosis (Contractor et al. 1989 : Ruschoff et al. 1990 : Ofner et al. 1990 : Kolar et al. 1992 : Delahunt et al. 1993 : Piffko et al. 1997 . With increasing mAgNOR counts. the percentage of nuclei with more than one AgNOR (pAgNOR>lI) increases. Recently. we showed that this new AgNOR parameter was a strong prognostic marker in glottic and oral squamous cell carcinomas (Xie et al. 1997a and b) .
In this study. we have investigated the expression of Bax and its significance regarding treatment failures in glottic squamous cell carcinomas. These results were compared with those obtained by AgNOR counts. i.e. mAgNOR and pAgNOR>l. We also tested whether the combination of the proliferative-and apoptosisrelated parameters could enhance the predictive power regarding the disease-free period. (v/v) hydrogen peroxide in methanol (45 s) to block endogenous peroxidase, followed by incubation with 95% and 70% ethanol (15 s each), distilled water (1 min) and phosphate-buffered saline (PBS) (5 min). They were then heated in a pressure cooker for 5 min in 10 mm citric acid buffer (pH 6.0), followed by rinsing in lukewarm tap water. The sections were then placed in TBS (Trisbuffered saline, pH 7.8) for 5 min and then blocked in TNK buffer (100 mM Tris, pH 7.6-7.8,550 mm sodium chloride, 10 mM potassium chloride), which contained 2% (w/v) bovine serum albumin (BSA), 0.1% Triton X-100 and 1% normal goat serum. A rabbit anti-human Bax polyclonal antibody (Santa Cruz Biotechnology, CA, USA; 1:20 dilution of 100 gg ml-' stock made up in TNK buffer) was added and the sections incubated overnight in a humidified chamber placed in the refrigerator. They were then washed once with PBS and incubated for 1 h at room temperature in a humidified chamber with biotinylated goat anti-rabbit antibody (1:500) made up in TNK buffer, followed by washing with PBS. They were then incubated for 30 min at room temperature with streptavidin horseradish peroxidase (1:20) made up in TNK buffer, then in development solution containing 0.06% diaminobenzidine (DAB) and 0.1% (v/v) hydrogen peroxide made up in TNK buffer (without goat serum, BSA and Tnton XI00) and finally counterstained with haematoxylin and mounted All sections were reviewed in conjunction by two of the authors (XX and OPFC) and classified according to estimates of percentages of cells stained and staining intensity. The percentages of positive tumour cells were graded into four classes: class 0, 0%; class 1, 1-30%; class 2, 31-70%; and class 3, 70-100%. The staining intensity was classified into five classes: negative, 0; weak. 0.5; moderate, 1; intense, 1.5; and very intense, 2. The intensity of the imunostaiing sometimes appeared heterogeneous. Having considered the whole tumour area, we classified the degree of Bax expression according to the most prevailing intensity. Muscular tissue and/or normal epithelium, which was present in nearly all sections, served as intemal control for the staining intensity and was classified as 1. Occasional disagreement regarding the classification was discussed and a consensus reached. The estimates both for the percentage of cells stained and for the intensity were then added and grouped as follows: 0-1.5, score 0; 2.0-3.0, score 1; 3.5-4.0, score 2; and exceeding 4.5, score 3. A Bax score of 0 was found in ten cases, score 1 in 14 cases, score 2 in 29 cases and score 3 in 16 cases.
MATERIAL AND METHODS

Patients
AgNOR staining and evaluation
The staining and counting were performed according to the method previously described (Ploton et al, 1986; Xie et al, 1997a) .
In brief, the sections were dewaxed and rehydrated. The silver reaction was performed with a freshly prepared solution of two parts of 50% silver nitrate in distilled, deionized water and one part of 2% gelatin in 1% formic acid for 45 min at room temperature. After thorough washing, the sections were placed in 5% sodium thiosulphate, dehydrated and mounted. The sections were stored in a dark cool place.
In each section, five fields were evaluated using a 100x oil immersion lens. The first field was subjectively selected, and the subsequent fields were systematically chosen roughly proportional 3. Figure 1 . the Bax expression was significantly lower in patients in whom the treatment failed than in those in whom the treatment was successful (P = 0.002). Both for pAgNOR>>l and mAgNOR counts. the scores were lower for TI-2 compared with T3-4 tumours (P = 0.001). pAgNOR>l ( Figure 2 ) and mAgNOR scores were lower in non-failures than in failures (P = 0.001 and 0.0 17 respectively). Loo-rank analysis showed that the Bax expression and both pAgNOR>l and mAgNOR counts were statistically significant in relation to the length of the disease-free period (Table 1) . Because of the particular selection used in this material. no significant correlation could be expected regarding T-classification. Figure 3 presents the Kaplan-Meier plots for the Bax expression in relation to the disease-free period (P = 0.0106) and Figure 4 the corresponding relationship regarding pAgNOR>I (P = 0.0003). A scatter diagram ( Figure 5 ) combining Bax and pAgNOR>l shows that there was no association between these two parameters. discnrminating failures and non-failures (see Figures 1 and 2) urged us to test the possible significance of combining the two parameters. When the Bax score was subtracted from the pAgNOR>l score. we found that this combined parameter appeared to be a statistically stronger prognostic factor than the respective single parameters. A similar combination of mAgNOR and Bax expression also emerged as a strong prognostic predictor (Table 2 ). Figure 6 presents the Kaplan-Meier plot regarding the disease-free period for the combined pAgNOR>l score-Bax score (P < 0.0001). This parameter predicted all but four of the 33 failures and 34 of the 36 non-failures. Further improvement in the discrimination between prognostic favourable and poor cases may be obtained by a posterion classification for Bax expression and AgNOR values, but this has not been tested. In relation to the prognosis. a complex association between the two parameters was found. Low scores for pAgNOR>l and high scores for Bax expression correlated with a favourable prognosis. whereas low scores for Bax expression and high scores for pAgNOR>l was associated with a poor prognosis. The inverse relationship between the Bax expression and pAgNOR>1 in
DISCUSSION
In this study. we show that low, Bax expression correlated with poor prognosis and high expression with a favourable prognosis in glottic squamous cell carcinomas. These findings are in agreement with the results of recent studies on patients treated with chemotherapy for metastatic breast adenocarcinomas (Krajewski et al. 1995) and with the prognosis in low-grade urinary bladder cancer (Gazzaniga et al. 1996) . How the Bax protein promotes apoptosis is uncertain, but several in vivo and in vitro studies have shown that Bax protein expression correlates with response to radio-and chemotherapy (Krajewski et al. 1995; Bargou et al. 1996: Chresta et al, 1996 : Kitada et al, 1996 : Sakakura et al. 1996 : Stoetzer et al. 1996 : Thomas et al. 1996 : Wagener et al. 1996 . As the majority of patients included in this series received radiotherapy alone as primary treatment. high Bax expression may be interpreted as an indicator of response to radiotherapy.
Most of the previous studies on squamous cell carcinomas of the head and neck have used the mAgNOR counting method (Pich et al. 1991 : Sano et al. 1991 : Bockmil et al. 1992 : Hirsch et al. 1992 . These studies show variation in overall mAgNOR count ranging from 4.3 to 15.1 (Bockmdl et al. 1992 : Hirsch et al. 1992 ).
Methodological problems, such as staining technique. variation in section thickness and the unambiguous identification of all AgNORs. may explain the diversity in mean AgNOR counts. The other counting method used in this study is a modification of the method introduced by Mourad and co-workers (Mourad et al. 1992 ).
Britsh Joumal of Cancer (1998) Contrary to their study. we have in our previous studies (Xie et al. 1997a and b) (Mirre and Knibiehler. 1982: Carbajo et al. 1993 ). The number of AgNORs increase from early G,-phase to late S-/G,-phases (Carbajo et al. 1993 : Ruschoff et al. 1994 . Further evidence for the idea that AgNOR counts represent a marker for proliferative activity has been presented in a study using double staining with Ki67 and AgNOR (Mourad et al. 1994 ). While Ki67-negative cells only had one to three. the Ki67-positive cells had 2-12 AgNORs. Similarly. both pAgNOR and mAgNOR counts have been found to correlate with other proliferative markers. such as the S-phase fraction. the BrdU-labelling index and Ki67 labelling index (Mourad et al, 1992 (Mourad et al, . 1993 (Mourad et al, . 1994 . These findings suggest that pAgNOR>l reflects some aspects of the tumour proliferative activity. as does the mean AgNOR score. Because of the simplicity of the pAgNOR>l counting method and a higher degree of reproducibility. pAgNOR>l rather than mAgNOR is. in our view. the preferred AgNOR parameter (Xie et al. 1997a and b) .
Despite the fact that T-stage in glottic carcinomas correlates well with prognosis (Vermund et al. 1990 ). we found no association between Bax expression and T-stage. The reason for this somewhat contradictory finding may be that the Bax expression was not a statistically strong parameter and that the two parameters pick out different groups of patients. Neither did we find any correlation between Bax expression and pAgNOR>l or mAgNOR scores. This is consistent with the results of a study on breast adenocarcinomas in which the S-phase fraction was used as a parameter reflecting the proliferative activity (Krajewski et al. 1995 ).
When we combined Bax expression and pAgNOR> I for treatment response (see Figures 5 and 6 ). a strong cooperative relationship between these two variables emerged that predicted 29 of the 33 failures and 34 of the 36 non-failures.
Our investigation confirms that AgNOR enumeration is a prognostic marker and further suggests that Bax expression is a potential prognostic marker. Whereas Bax expression may reflect the response to radiation-induced apoptosis, AgNOR counts appear to be a measure of some aspects of the proliferative activity. The combination of these two parameters emerged as a strong discriminator regarding treatment failures in non-metastatic glottic carcinomas. Thus, strategies combining assessment of tumour proliferation and apoposis-related proteins may prove to be fruitful in the search for new prognostic tumour markers in squanmous cell carcinomas of the head and neck.
